palatin造句

• Palatin shares rose 1 / 8 to 8 1 / 8.
• Palatin has completed a human phase IIb study utilizing subcutaneous administration and reported positive results.
• He then began playing the guitar professionally with Edu醨d Palatin and Elek Lakatos as mentors.
• Palatin has since re-initiated bremelanotide studies for ED and FSD using a subcutaneous delivery method.
• Inside the castle is also present a " palatin chapel ", dedicated to the saints James.
• "There are no soldiers here, " said 25-year-old Palatin Magabe.
• "There are no soldiers here, " said 25-year-old Palatin Magabe.
• -- Palatin Technologies : a peptide molecule derivative called PT-14; in the earliest test stages.
• Palatin . gr . " 278 ) indicates that it belonged to George Kantakouzenos while he was living at Smederevo.
• The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, Glaxo Group Research, and Roche Research Centre.
• The chairman, Stefan M . Palatin, owns more than half the stock through three Panamanian companies based in Switzerland or Austria.
• Palatin's agent has the potential to earn " well over $ 100 million " in annual sales, Quilty said.
• In 2014, Palatin, the company developing the drug, announced the beginning of a Phase 3 clinical trial to determine its effectiveness.
• In 2011, these were Cassie Taylor, Dani Wilde and Samantha Fish as'Girls With Guitars'supported by drummer Denis Palatin.
• The company does business with other companies linked to Palatin, who has assumed a $ 5 million debt to Cronos incurred by one such outfit.
• Princeton, New Jersey-based Palatin said today it expects to complete all of its studies and apply for FDA approval by the end of 1998.
• "' Pavel Vladimirovich Palatin "'(; born March 12, 1962 ) is a Russian professional football coach and a former player.
• The FDA next year is expected to approve its use in diagnosing atypical appendicitis, said manufacturer Palatin Technologies Inc . The Walter Reed experiment marks its first attempted use against anthrax.
• Positive results of bremelanotide in the treatment of hypoactive sexual desire disorder ( HSDD ) in two late-stage phase III clinical trials were announced by Palatin on 1 November 2016.
• "' PL-6983 "'is a MC 4 receptor agonist which is under development by Palatin Technologies for the treatment of female sexual dysfunction and erectile dysfunction.